Biocept Inc (NASDAQ:BIOC) a major commercial provider firm of clinically actionable liquid biopsy assessments designed to enhance the outcomes of cancer patients, reported that it has finalized an in-network provider deal with BCBSTX, the leading provider of health benefits in the state.
The management speaks
Veena Singh, the Senior VP of Biocept, said that defining the molecular position of a tumor can assist physicians individualize cure for their patients and their Target Selector™ platform can offer this important data from a simple blood sample. The liquid biopsy assessment is changing the way physicians assess tumor status and monitor both resistance and response to treatment.
Michael Nall, the President and CEO of Biocept, said that it is pleasing that health plans are witnessing the value of their liquid biopsy approach for monitoring and profiling important cancer biomarkers. Associating with health insurers is a prime focus of their business plan, as it may improve physician access to latest non-invasive technology for their subjects and offer timely adjudication of claims for patients.
The scope
Finalizing this in-network deal is an important achievement for company, as Texas is one of their largest markets while BCBSTX is the leading provider in that state. Following this agreement, the count of people with in-network access to their tests has grown to almost 185 million, with certain members having access through multiple plans.
Biocept is a molecular diagnostics firm with commercialized assays for gastric, colorectal, lung, breast and prostate cancers, and melanoma. The firm utilizes its proprietary liquid biopsy know-how to provide physicians with data for monitoring and treating patients suffering with cancer. The firm’s Target Selector™ liquid biopsy know-how platform analyzes and captures tumor-associated molecular markers in circulating tumor cells as well as and in plasma.
With numerous of tests planned, the platform has shown the ability to pinpoint cancer mutations and alterations to notify physicians about a patient’s illness and therapeutic alternatives.
THE MORNING REPORT
Start your workday the right way with the news that matters most.
Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy
